Who are Enzalutamide Soft Capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ODM-201 Tablet A, Maximum androgen blockade, Zoladex and Casodex, Darolutamide Oral Tablet, Darolutamide (BAY 1841788), Darolutamide intermittent.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/enzalutamide-soft-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Enzalutamide Soft Capsules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enzalutamide Soft Capsules (Enzalutamide Soft Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen receptor antagonist. Area: Oncology.

phase 3 Androgen receptor antagonist Androgen receptor (AR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Enzalutamide Soft Capsules (Enzalutamide Soft Capsules) — Jiangsu HengRui Medicine Co., Ltd.. Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, preventing androgen-driven gene transcription in prostate cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Enzalutamide Soft Capsules TARGET	Enzalutamide Soft Capsules	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Androgen receptor antagonist	Androgen receptor (AR)
ODM-201 Tablet A	ODM-201 Tablet A	Orion Corporation, Orion Pharma	marketed	Androgen receptor antagonist	Androgen receptor (AR)
Maximum androgen blockade	Maximum androgen blockade	Wonju Severance Christian Hospital	marketed	Androgen receptor antagonist combination therapy	Androgen receptor; testosterone synthesis pathway
Zoladex and Casodex	Zoladex and Casodex	AstraZeneca	marketed	GnRH agonist (Zoladex) and androgen receptor antagonist (Casodex)	GnRH receptor (Zoladex); androgen receptor (Casodex)
Darolutamide Oral Tablet	Darolutamide Oral Tablet	Santa Chiara Hospital	marketed	Androgen receptor antagonist	Androgen receptor (AR)
Darolutamide (BAY 1841788)	Darolutamide (BAY 1841788)	Canadian Cancer Trials Group	phase 3	Non-steroidal androgen receptor antagonist	Androgen receptor (AR)
Darolutamide intermittent	Darolutamide intermittent	The First Affiliated Hospital with Nanjing Medical University	phase 3	Androgen receptor antagonist	Androgen receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen receptor antagonist class)

Santa Chiara Hospital · 2 drugs in this class
Cassiopea SpA · 2 drugs in this class
The First Affiliated Hospital with Nanjing Medical University · 2 drugs in this class
Pfizer · 2 drugs in this class
Suzhou Kintor Pharmaceutical Inc, · 1 drug in this class
AEterna Zentaris · 1 drug in this class
University of Sydney · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enzalutamide Soft Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/enzalutamide-soft-capsules. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing